Using private electronic patient records to help create new medicines and provide medical help.
Fujitsu Limited and TOPPAN Holdings Inc. have solidified their business alliance, set to make waves in the burgeoning field of medical big data. Their partnership is driven by a shared vision to leverage Japan’s next-generation Medical Infrastructure Act for advancing research and development using medical big data, ultimately striving towards a healthier and longer-lived society while fostering new industries and businesses.
The alliance hinges on combining analytical prowess with data cleansing technology within an anonymised electronic medical record database. This synergy aims to enhance the precision of extensive medical data analysis and the delivery of services that support medical care research and development. Future endeavours will centre on the joint promotion of various medical and health data, including anonymised electronic medical records, catering to customers across Japan.
The company has prioritised “Digital & Sustainable Transformation” as its core concept, spotlighting healthcare as a pivotal growth area. Their commitment to digital transformation (DX) aligns with their strategy to propel the medical big data business, leveraging analysis services grounded in anonymised electronic medical record data held by the Japan Medical Association Medical Information Management Organization (J-MIMO), a certified producer of anonymised medical information under the Next Generation Medical Infrastructure Act.
Fujitsu, through its Uvance initiative aimed at realising a sustainable world, underscores “Healthy Living” to enhance the life experiences of all individuals. Fujitsu’s expertise is evident in its market-leading electronic medical record system business and data cleansing technology. They also harness AI technologies, including medical data analysis technology, to facilitate data utilisation in the medical field. The partnership’s primary objectives encompass expanding data, particularly anonymised electronic medical records, for enhanced data analysis. Additionally, it involves integrating both companies’ medical data proficiency with their data platforms to offer advanced analysis services to pharmaceutical companies and medical institutions.
Development and provision of data analysis services
The company will integrate J-MIMO’s anonymised electronic medical record data into its “DATuM IDEA” medical information analysis service. Fujitsu’s data cleansing platform will standardise medical data from various hospitals, enabling precise analysis. This will accelerate drug safety and efficacy evaluations, facilitating more efficient drug development and personalised medicine. The latter will craft SaaS analytics services for pharmaceutical companies and medical institutions utilising anonymised electronic medical record data. Their services will encompass medical data visualisation and ad hoc analysis, fostering the use of medical AI models for prediction and forecasting in research and development.
Expansion of electronic medical record data for analysis
Both companies will collaborate with medical institutions and J-MIMO to gather previously untapped data elements, such as discharge summaries and nursing and surgical records. This data augmentation will offer a comprehensive view of individual patient conditions, promoting the realisation of personalised medicine. In the foreseeable future, this partnership will propel data-driven initiatives to extend healthy life expectancy and foster a sustainable society. Joint analysis and research on electronic medical record data will be pivotal in achieving these goals.
This strategic alliance marks a significant step forward in harnessing medical big data for bettering healthcare and society, aligning with Japan’s progressive regulatory framework for anonymised medical data utilisation. Their collaborative efforts promise to drive innovation and contribute to a healthier, more sustainable future.
